Lavo AI: AI Crystal Structure Prediction for Drug Dev

Lavo Life Sciences is a VC-backed startup tackling one of pharma's trickiest challenges: predicting how a drug molecule will crystallize before it becomes an expensive late-stage problem. Their flagship platform, Crystal Console, harnesses AI to accelerate crystal structure prediction for small molecule drugs, giving computational chemists and formulation scientists a clearer view into solid-state behavior long before physical testing begins. Rather than relying solely on time-consuming experimental screening, Crystal Console lets teams import, visualize, and analyze crystal structures through a web-based interface built for speed and clarity. Virtual polymorph screening surfaces potential risks—like unexpected polymorphic forms—early in development, while integrated PXRD analysis allows users to compare experimental diffraction data against predicted structures for validation. The result is a more informed, data-driven approach to solid-state formulation. For drug development teams under pressure to move fast without sacrificing rigor, Lavo AI offers a way to catch crystal form issues before they derail a program. By combining AI-driven prediction with practical crystallography tools, the platform aims to shorten development timelines and reduce the financial risk tied to unstable or poorly characterized crystal forms.

Get started by booking a demo with the Lavo Life Sciences team to see Crystal Console in action. Once onboarded, import your small molecule crystal structure data into the platform and use the visualization tools to explore and analyze structural details. Run virtual polymorph screening to flag potential risk areas in your compound's solid-state behavior. Use the PXRD analysis feature to cross-check experimental diffraction patterns against AI-predicted structures, helping validate findings and inform formulation decisions.